Discussions around AI prescriber data sharing show how safety research for AI tools intersects with patient privacy and commercial protections. In a recent case, some physicians requested safety data from an AI prescriber, while the developer, Doctronic, said data sharing wasn’t feasible. A Utah authority denied the inquiry, arguing that scientific interest does not outweigh Doctronic’s business confidentiality interests. This context highlights a broader question: when should safety information from AI systems be accessible to clinicians and researchers, and under what safeguards?
What happened in the case
The scenario involves a request from clinicians for safety-related data about an AI prescriber system. The company asserted limits on data sharing, citing confidential business information. State officials rejected the inquiry, emphasizing that protecting confidential interests can conflict with broader safety investigations. While the specifics vary by jurisdiction, the core tension remains the same: how to balance transparency that supports patient safety with protections that support innovation and competitive positioning.
Why safety data matters for AI in medicine
Safety data helps clinicians understand how an AI prescriber performs across real-world settings, including error rates, failure modes, and the conditions that affect accuracy. Without access to such data, clinicians may rely on general assumptions rather than context-specific evidence, potentially impacting patient outcomes. For researchers, safety data can guide revisions to algorithms, thresholds for alerts, and boundaries for use. Yet safety signals often involve sensitive details about proprietary models, vendor relationships, and commercial strategies, which complicates data sharing.
Legal and regulatory landscape
Across regions, healthcare data carries strong privacy protections. When safety data is shared for research or regulatory purposes, it typically requires careful governance, de-identification, and clear data-use agreements. Regulators increasingly look at whether data-sharing practices support patient safety and whether there are legitimate, well-defined pathways to obtain data. At the same time, businesses may invoke confidentiality interests to protect trade secrets or competitive advantages. In practice, entities often negotiate frameworks that enable limited data access under strict controls, with oversight to ensure privacy and safety goals are not compromised.
Balancing interests: science vs business
Striking the right balance requires transparent governance and clearly defined safeguards. On one side, safety data can accelerate learning, improve risk assessment, and inform guidelines for AI-assisted care. On the other side, companies may argue that releasing certain data could undermine innovation or reveal sensitive commercial information. To bridge these concerns, several measures are commonly discussed:
- Data de-identification and minimization to reduce privacy risk
- Limiting access to qualified researchers with data-use agreements
- Redacting proprietary model details while sharing high-level safety outcomes
- Time-bound access and audit trails to ensure accountability
- Independent governance bodies to review data requests
What clinicians and researchers can do
Clinicians and researchers seeking safety data can pursue structured, principle-based approaches. Start with clear research questions and specify the data elements needed, the intended use, and safeguards for privacy. When direct data sharing is limited, consider alternatives such as synthetic data that preserves patterns without exposing real patient or proprietary details, or access to aggregate safety metrics. Collaborations can be formalized through data-use agreements that define roles, responsibilities, and review processes. Transparency about methods and limitations helps users interpret AI-driven findings responsibly.
Key takeaways
- Safety data from AI systems is essential for clinician trust and patient protection, but sharing must respect privacy and business protections.
- Governance frameworks help balance scientific interest with confidential business information.
- Practical data-sharing options include de-identified data, aggregate results, and synthetic datasets.